The pharmaceutical company Roche there is a major change in the leadership. The longtime head of the pharmaceuticals division Daniel O'day, will leave at the end of the year, the company after 31 years. His successor, William Anderson, the current CEO of the US subsidiary Genentech.
O'day is, according to Roche-message from the Assembly by 31. December is stepping down from his Position. Until the end of February 2019 O'day will ensure a smooth Handover of the activities to his successor, before he takes on new responsibilities outside the company.
for This purpose, had reported on Monday the media that O'day will be the US group Gilead exchange, where starting next year, the successor of John Milligan. This was declared in July, to vacate by the end of the year his Post as CEO of the US company.
Many drugs on the market
When Roche brought the current head of the US subsidiary Genentech, William (Bill) Anderson, the Post of O'day will take over as the group announced. Anderson will be working in Basel, and as a member of the Executive Committee to Severin Schwan, CEO of Roche, reports.
In the communication, Swan stresses the numerous medicines, the Roche O'day at the pharmaceutical top over the years on the market. In addition, the difference have contributed to the end of Manager a significant contribution to the excellent positioning, Roche am today.
exchange from the United States: Bill Anderson is currently the chief of subsidiary Genentech, the Basel pharmaceutical company. (Photo: PD)
at the same time, Roche's chief stressed that, with Anderson, a Manager now come to the pharmaceutical tip, of the have an impressive record of success.
New member of VR
proposed in Addition, Roche announced that the Board of Directors at its December meeting, the first proposals to the annual General meeting of 5. March of 2019 I decided to go for it. The Board of Directors proposes to 2019 Hans Clevers, Professor of Molecular genetics, University Medical Center Utrecht, NL, for election to the Board of Directors.
For re-election to the Board of Directors, the following incumbent Board members: Christoph Franz, André Hoffmann and John Irving Bell, Julie Brown, Paul Bulcke, Anita Hauser, Richard P. Lifton, Andreas Oeri, Bernard Poussot, Claudia Süssmuth Dyckerhoff, Severin Schwan and Peter R. Voser be recommended. (ij/sda)
Created: 10.12.2018, 08:55 PM